Rate of response of individual asthma control measures varies and may overestimate asthma control: An analysis of the goal study

Journal of Asthma

Volumn 44, Issue 8, 2007, Pages 667-673

  Bateman, Eric D ^a,g   Clark, Tim J H ^b   Frith, Lucy ^c   Bousquet, Jean ^d   Busse, William W ^e   Pedersen, Soren E ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Asthma; Control; GOAL study; Salmeterol fluticasone propionate; Time

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG USE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NOCTURNAL ASTHMA; OUTCOME ASSESSMENT; PREDICTION; SYMPTOM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDIVIDUALITY; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; QUALITY OF LIFE;

EID: 35448975937     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900701554821     Document Type: Article

References (22)

1. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002. NIH Publication No. 02-3659.
2. British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network British guideline on the management of asthma, Thorax 2003; 58(Suppl I).
3. Malo JL, Cartier A, Ghezzo H, Lafrance M, McCants M, Lehrer SB. Patterns of improvement in spirometry, bronchial hyperresponsiveness, and specific IgE antibody levels after cessation of exposure in occupational asthma caused by snow-crab processing. Am Rev Respir Dis 1988; 138:807-812.
4. Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM, Badcock CA, Woolcock AJ. Optimal asthma control, starting with high doses of budesonide. Eur Respir J 2000; 16:226-235.
5. Woolcock AJ. What are the important questions in the treatment of asthma? Clin Exp All Rev 2001; 1:62-64.
6. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57:309-316.
7. Gibson PG, Wong BJ, Hepperle MJ, Kline PA, Girgis-Gabardo A, Guyatt G, Dolovich J, Denburg JA, Ramsdale EH, Hargreave FE. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992; 22:525-532.
8. Bateman ED, Boushey H, Bousquet J, Busse WW, Clark TJH, Pauwels RA, Pedersen SE; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004; 170:836-844.
9. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5-40.
10. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19:182-191.
11. Nelson HS. Advair: combination treatment with fluticasone propionate/ salmeterol in the treatment of asthma. J Allergy Clin Immunol. 2001; 107:398-416.
12. Reddel HK, Marks GB, Jenkins CR. When can personal best peak flow be determined for asthma action plans? Thorax 2004; 59:922-924.
13. Sont JK, Willems LNA, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159:1043-1051.
14. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721.
15. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173.
16. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53:91-95.
17. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, Taylor DR. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164:738-743.
18. Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A, Hargreave FE. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation J Allergy Clin Immunol 2000; 106:638-644.
19. Jenkins CR, Thien FCK, Wheatley JR, Reddel HK. Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 2005; 26:36-44.
20. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65.
21. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-907.
22. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99:553-558.